204. Hamstra, D. A., Kloet, E. R., Tollenaar, M. et al. (2016). Mineralocorticoid receptor haplotype moderates the effects of oral contraceptives and menstrual cycle on emotional information processing. Journal of Psychopharmacology, 30(10), 1054–1061. doi:10.1177/0269881116647504.
205. Desoto, M., Geary, D. C., Hoard, M. K. et al. (2003). Estrogen fluctuations, oral contraceptives and borderline personality. Psychoneuroendocrinology, 28(6), 751–766. doi:10.1016/s0306-4530(02)00068-9; Oinonen, K. A., & Mazmanian, D. (2002). To what extent do oral contraceptives influence mood and affect? Journal of Affective Disorders, 70(3), 229–240. doi:10.1016/s0165-0327(01)00356-1; Kutner, S. J., & Brown, W. L. (1972). History of depression as a risk factor for depression with oral contraceptives and discontinuance. Journal of Nervous and Mental Disease, 155(3), 163–169. doi:10.1097/00005053-197209000-00002.
206. Rasgon, N., Bauer, M., Glenn, T. et al. (2003). Menstrual cycle related mood changes in women with bipolar disorder. Bipolar Disorders, 5(1), 48–52. doi:10.1034/j.1399-5618.2003.00010.x.
207. Gingnell, M., Engman, J., Frick, A. et al. (2013). Oral contraceptive use changes brain activity and mood in women with previous negative affect on the pill: A double-blinded, placebo-controlled randomized trial of a levonorgestrel-containing combined oral contraceptive. Psychoneuroendocrinology, 38(7), 1133–1144. doi:10.1016/j.psyneuen.2012.11.006.
208. Svendal, G., Berk, M., Pasco, J. A. et al. (2012). The use of hormonal contraceptive agents and mood disorders in women. Journal of Affective Disorders, 140(1), 92–96. doi:10.1016/j.jad.2012.03.030; Skovlund, C. W., Mørch, L. S., Kessing, L. V., & Lidegaard, Ø. (2016). Association of hormonal contraception with depression. JAMA Psychiatry, 73(11), 1154–1162. doi:10.1001/jamapsychiatry.2016.2387; Toffol, E., Heikinheimo, O., Koponen, P. et al. (2011). Hormonal contraception and mental health: Results of a population-based study. Human Reproduction, 26(11), 3085–3093. doi:10.1093/humrep/der269.
209. Skovlund, C. W., Mørch, L. S., Kessing, L. V., & Lidegaard, Ø. (2016). Association of hormonal contraception with depression. JAMA Psychiatry, 73(11), 1154–1162. doi:10.1001/jamapsychiatry.2016.2387.
210. Bäckström, T., Hansson-Malmström, Y., Lindhe, B. et al. (1992). Oral contraceptives in premenstrual syndrome: A randomized comparison of triphasic and monophasic preparations. Contraception, 46(3), 253–268. doi:10.1016/0010-7824(92)90006-f; Bancroft, J., Sanders, D., Warner, P., & Loudon, N. (1987). The effects of oral contraceptives on mood and sexuality: A comparison of triphasic and combined preparations. Journal of Psychosomatic Obstetrics and Gynecology, 7(1), 1–8. doi:10.3109/01674828709019585.
211. Skovlund, C. W., Mørch, L. S., Kessing, L. V., & Lidegaard, Ø. (2016). Association of hormonal contraception with depression. JAMA Psychiatry, 73(11), 1154–1162. doi:10.1001/jamapsychiatry.2016.2387.
212. Ernst, U., Baumgartner, L., Bauer, U., & Janssen, G. (2002). Improvement of quality of life in women using a low-dose desogestrel-containing contraceptive: Results of an observational clinical evaluation. European Journal of Contraception and Reproductive Health Care, 7(4), 238–243. doi:10.1080/ejc.7.4.238.243.
213. Poromaa, I. S., & Segebladh, B. (2012). Adverse mood symptoms with oral contraceptives. Acta Obstetricia et Gynecologica Scandinavica, 91(4), 420–427. doi:10.1111/j.1600-0412.2011.01333.x; Freeman, E. W., Kroll, R., Rapkin, A.et al. (2001). Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. Journal of Women’s Health and Gender-Based Medicine, 10(6), 561–569. doi:10.1089/15246090152543148; Parsey, K. S., & Pong, A. (2000). An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception, 61(2), 105–111. doi:10.1016/s0010-7824(00)00083-4; Sillem, M., Schneidereit, R., Heithecker, R., & Mueck, A. O. (2009). Use of an oral contraceptive containing drospirenone in an extended regimen. European Journal of Contraception and Reproductive Health Care, 8(3), 162–169. doi:10.1080/ejc.8.3.162.169; Apter, D., Borsos, A., Baumgärtner, W. et al. (2003). Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. European Journal of Contraception and Reproductive Health Care, 8(1), 37–51. doi:10.1080/713604397.
214. Deijen, J., Duyn, K., Jansen, W., & Klitsie, J. (1992). Use of a monophasic, low-dose oral contraceptive in relation to mental functioning. Contraception, 46(4), 359–367. doi:10.1016/0010-7824(92)90098-e.
215. Schultz-Zehden, B., & Boschitsch, E. (2006). User experience with an oral contraceptive containing ethinylestradiol 30μg30 and drospirenone 3mg (Yasmin®) in clinical practice. Treatments in Endocrinology, 5(4), 251–256. doi:10.2165/00024677-200605040-00006; Short, M. (2009). User satisfaction with the combined oral contraceptive drospirenone 3 mg/ethinylestradiol 20 μg (Yasminelle®) in clinical practice. Clinical Drug Investigation, 29(3), 153–159. doi:10.2165/00044011-200929030-00002.
216. Cheslack-Postava, K., Keyes, K. M., Lowe, S. R., & Koenen, K. C. (2015). Oral contraceptive use and psychiatric disorders in a nationally representative sample of women. Archives of Women’s Mental Health, 18(1), 103–111. doi:10.1007/s00737-014-0453-4; Lopez, L., Kaptein, A., & Helmerhorst, F. (2012). Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd006586.
